Back to results

CompletedPhase 2

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

NCT00228150

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Sanofi-Aventis Administrative Office

Vienna, Austria

+12 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2003-07
Enrollment: 564 participants
Sponsor: Sanofi
Purpose: treatment

Locations (13)

Sanofi-Aventis Administrative OfficeVienna, Austria
Sanofi-Aventis Administrative OfficeLaval, Canada
Sanofi-Aventis Administrative OfficeHørsholm, Denmark
Sanofi-Aventis Administrative OfficeParis, France
Sanofi-Aventis Administrative OfficeBerlin, Germany
Sanofi-Aventis Administrative OfficeCasablanca, Morocco
Sanofi-Aventis Administrative OfficeGouda, Netherlands
Sanofi-Aventis Administrative OfficePorto Salvo, Portugal
Sanofi-Aventis Administrative OfficeMidrand, South Africa
Sanofi-Aventis Administrative OfficeBarcelona, Spain
Sanofi-Aventis Administrative OfficeBromma, Sweden
Sanofi-Aventis Administrative OfficeMégrine, Tunisia
Sanofi-Aventis Administrative OfficeGuilford Surrey, United Kingdom

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease — TrialFind